Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2010 | 09-2010 | 06-2010 | 03-2010 | 12-2009 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -11,185 | -8,215 | -3,547 | -1,287 | -5,145 |
| Depreciation Amortization | 1,439 | 404 | 11 | -65 | 603 |
| Accounts receivable | -335 | -24 | 33 | -1 | 0 |
| Other Working Capital | -484 | -35 | 52 | -75 | -306 |
| Other Operating Activity | 2,831 | 2,914 | 488 | 201 | 588 |
| Operating Cash Flow | $-7,733 | $-4,956 | $-2,963 | $-1,227 | $-4,260 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -215 | -166 | -145 | -35 | -61 |
| Net Acquisitions | 3,876 | -80 | -80 | N/A | N/A |
| Purchase Sale Intangibles | -215 | -215 | -215 | -215 | N/A |
| Other Investing Activity | -464 | -461 | -211 | -211 | 15 |
| Investing Cash Flow | $3,197 | $-708 | $-436 | $-246 | $-46 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 2,310 |
| Debt Repayment | N/A | N/A | N/A | N/A | -264 |
| Common Stock Issued | 25,768 | 18,673 | 9,041 | 456 | 14,465 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -28 |
| Financing Cash Flow | $25,768 | $18,673 | $9,041 | $456 | $16,483 |
| Exchange Rate Effect | -96 | -9 | 6 | N/A | N/A |
| Beginning Cash Position | 12,189 | 12,421 | 12,407 | 12,189 | 12 |
| End Cash Position | 33,325 | 25,422 | 18,056 | 11,173 | 12,189 |
| Net Cash Flow | $21,136 | $13,001 | $5,649 | $-1,016 | $12,177 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,733 | -4,956 | -2,963 | -1,227 | -4,260 |
| Capital Expenditure | -221 | -166 | -145 | -35 | -61 |
| Free Cash Flow | -7,954 | -5,122 | -3,108 | -1,261 | -4,321 |